IsoRay

IsoRay Days Payable Outstanding

Delisted

The Days Payable Outstanding (DPO) of IsoRay (ISR) as of Nov 4, 2026 is 57.06. In the previous year, Days Payable Outstanding (DPO) was 54.02 — a change of 5.62% (higher).

Days Payable Outstanding

57.06

YoY

5.62%

Last updated:

Days Payable Outstanding (DPO) of IsoRay is 2022 57.06 . Days Payable Outstanding (DPO) of IsoRay was 2021 54.02 . It decreases by 5.62% higher compared to the previous year.

The IsoRay Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2015
40.97 USD
Jan 1, 2016
48.03 USD
Jan 1, 2017
58.62 USD
Jan 1, 2018
124.41 USD
Jan 1, 2019
58.42 USD
Jan 1, 2020
52.39 USD
Jan 1, 2021
54.02 USD
Jan 1, 2022
57.06 USD
The IsoRay Days Payable Outstanding history
YEARDays Payable OutstandingYoY
57.06+5.62%
54.02+3.11%
52.39-10.32%
58.42-53.04%
124.41+112.25%
58.62+22.04%
48.03+17.24%
40.97-13.78%
47.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IsoRay Stock analysis

What does IsoRay do? The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations. IsoRay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IsoRay stock

Days Payable Outstanding (DPO) of IsoRay is 57.06 in 2022.

Days Payable Outstanding (DPO) of IsoRay changed from 54.02 to 57.06, representing a 5.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) IsoRay since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s IsoRay with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — IsoRay

All Key Metrics — IsoRay